Media reported on a study conducted by researchers from the INRA Institute in Toulouse, France. This explorative study has severe limitations; the biological significance of the observed biochemical parameter with respect to adversity is not demonstrated. Statements relating the study results to humans would therefore be misleading speculation.
Media reported on a study on zebra fish undertaken by the Institute of Functional Genomics of Lyon. The study is highly experimental, is not relevant for human risk assessment and does not show any direct link between BPA exposure and effects on humans.
Industry stresses that BPA based products manufactured under EU standards are safe and continue to remain safe.
Industry remains convinced that there is no basis to change the current classification of BPA. BPA is not a selective reproductive toxicant as indicated by guideline studies that cover a very wide dose range, from very low up to high doses. Effects on animal fertility only occur at high doses of BPA and are a consequence of systemic toxicity.
Industry provides background briefing on latest EFSA draft assessment on BPA.
SCENIHR preliminary opinion finds margin of safety for polycarbonate and epoxy resin medical devices. Within the constraints of the available data, SCENIHR generally found that exposure to BPA from all medical applications is low, often in the range of the very low consumer exposures through the diet.
Industry stresses that in its new draft opinion, EFSA did not conclude that BPA causes effects on the liver, kidney and the mammary gland at dose levels relevant to human exposure, but identified these areas to require risk assessment. Additionally it set a new temporary TDI (t-TDI) as a result of a highly conservative approach and not of increased uncertainty. Finally, industry points out that exposure to BPA for consumers remains extremely low and is well below the new t-TDI.
Industry provides a number of questions and answers on the latest EFSA draft health assessment of BPA.
EFSA’s draft opinion clearly confirms that BPA is not a concern for human health, including newborns and young children. This is consistent with the findings of other regulatory agencies across the globe.